Date: Saturday, June 11, 2016
Session Name: Poster Session A: Kidney: Acute Cellular Rejection
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
The risk of subclinical histological changes in renal allografts with ALZ induction is not well defined. Hence, we performed a retrospective analysis of 527 surveillance biopsies performed between 2/15/2009 to 12/26/2011 in 351 patients. 40% were females and 48% Black. 60% of patients received alemtuzumab, 25% basiliximab and 16% rATG for induction. Biopsies were reviewed using Banff scoring system.
The time to first biopsy was 4.0+/-2.1 for the first and 13.4+/-4.0 months for the second biopsy. The findings are summarized in the tables. Chronic histological findings including vascular changes were comparable between the three groups.
Our findings indicate that patients who received ALZ experienced similar rate of subclinical rejection when compared with other induction agents. Therefore surveillance biopsies are warranted after ALZ induction to recognize subclinical histological changes that could impact allograft outcomes and would require modification of the immunosuppressive regimen.
CITATION INFORMATION: Madariaga H, Ugarte R, Drachenberg C, Costa N, Thomas B, Bromberg J, Weir M, Haririan A. Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Madariaga H, Ugarte R, Drachenberg C, Costa N, Thomas B, Bromberg J, Weir M, Haririan A. Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/surveillance-biopsy-findings-with-alemtuzumab-alz-induction-in-kidney-transplantation/. Accessed January 27, 2021.
« Back to 2016 American Transplant Congress